SARS-CoV-2 阳性母亲所生后代的病毒阳性率及母婴传播时机:动态系统评价与荟萃分析
该动态系统评价与荟萃分析纳入 472 项研究(206 项队列研究、266 项病例系列和病例报告;28 952 名母亲,18 237 名婴儿),评估 SARS-CoV-2 感染母亲所生婴儿的病毒阳性率、母婴传播时机及围产结局。14 271 名婴儿中 1.8%(95%CI 1.2% 至 2.5%)RT-PCR 阳性;592 名阳性婴儿中 14 例确诊母婴传播(宫内 7 例/448 例评估,产时 2 例/18 例评估,产后早期 5 例/70 例评估)。母亲重症 covid-19(OR 2.4,95%CI 1.3 至 4.4)、母亲死亡(OR 14.1,95%CI 4.1 至 48.0)、母亲入住 ICU(OR 3.5,95%CI 1.7 至 6.9)及母亲产后感染(OR 5.0,95%CI 1.2 至 20.1)与后代 SARS-CoV-2 阳性相关。阳性率存在地区差异,北美 0.1%(95%CI 0.0% 至 0.3%),拉丁美洲和加勒比地区 5.7%(95%CI 3.2% 至 8.7%)。
要点
- 14 271 名 SARS-CoV-2 感染母亲所生婴儿中,RT-PCR 阳性率为 1.8%(95%CI 1.2% 至 2.5%)。
- 592 名阳性婴儿中确诊母婴传播 14 例:宫内 7 例(448 例评估)、产时 2 例(18 例评估)、产后早期 5 例(70 例评估)。
- 母亲重症 covid-19(OR 2.4,95%CI 1.3 至 4.4)、母亲死亡(OR 14.1,95%CI 4.1 至 48.0)、母亲入住 ICU(OR 3.5,95%CI 1.7 至 6.9)、母亲产后感染(OR 5.0,95%CI 1.2 至 20.1)与后代阳性相关。
- 800 名有结局数据的阳性婴儿中,死产 20 例、新生儿死亡 23 例、早期妊娠丢失 8 例,749 名存活至随访结束。
- RT-PCR 阳性率地区差异大:北美 0.1%(95%CI 0.0% 至 0.3%),拉丁美洲和加勒比地区 5.7%(95%CI 3.2% 至 8.7%)。
适用人群与场景
- 因任何原因寻求医院照护且诊断为 SARS-CoV-2 感染的孕妇和近期孕妇(包括流产或流产后)。
- 纳入报告后代 SARS-CoV-2 状态及阳性危险因素的队列研究;病例系列和病例报告用于评估阳性婴儿的母婴传播时机和可能性。
诊断标准与关键阈值
- 采用世界卫生组织分类将母婴传播时机分为宫内、产时和产后早期。
- 后代 SARS-CoV-2 阳性通过逆转录聚合酶链反应(RT-PCR)检测确认。
研究设计与关键结果
- 动态系统评价与荟萃分析纳入 472 项研究(206 项队列研究、266 项病例系列和病例报告;28 952 名母亲,18 237 名婴儿)。
- 14 271 名 SARS-CoV-2 感染母亲所生婴儿中 1.8%(95%CI 1.2% 至 2.5%;140 项研究)RT-PCR 阳性。
- 592 名有暴露时机及检测类型和时机数据的 SARS-CoV-2 阳性婴儿中,14 例确诊母婴传播:宫内 7 例(448 例评估)、产时 2 例(18 例评估)、产后早期 5 例(70 例评估)。
- 800 名有结局数据的 SARS-CoV-2 阳性婴儿中,死产 20 例、新生儿死亡 23 例、早期妊娠丢失 8 例;749 名婴儿存活至随访结束。
- 母亲重症 covid-19(OR 2.4,95%CI 1.3 至 4.4)、母亲死亡(OR 14.1,95%CI 4.1 至 48.0)、母亲入住 ICU(OR 3.5,95%CI 1.7 至 6.9)、母亲产后感染(OR 5.0,95%CI 1.2 至 20.1)与后代 SARS-CoV-2 阳性相关。
- RT-PCR 阳性率存在地区差异:北美 0.1%(95%CI 0.0% 至 0.3%),拉丁美洲和加勒比地区 5.7%(95%CI 3.2% 至 8.7%)。
证据类型、等级与局限
- 研究设计:动态系统评价与荟萃分析,检索 2019 年 12 月 1 日至 2021 年 8 月 3 日主要数据库,采用随机效应模型合并率,关联用比值比和 95% 置信区间报告,不适宜荟萃分析时进行叙述性综合。
- 证据类型:纳入队列研究、病例系列和病例报告;系统评价注册号 PROSPERO CRD42020178076。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,SARS-CoV-2 感染母亲所生婴儿的 SARS-CoV-2 阳性率低,证据提示存在确诊的 SARS-CoV-2 垂直传播,但可能罕见,母亲 covid-19 严重程度似乎与后代 SARS-CoV-2 阳性相关。
- 本文为动态系统评价,将根据新证据更新,更新可能在原文发表后两年内进行。
指南或共识出处
- 本文为动态系统评价与荟萃分析,注册号 PROSPERO CRD42020178076,发表于 BMJ。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To assess the rates of SARS-CoV-2 positivity in babies born to mothers with SARS-CoV-2 infection, the timing of mother-to-child transmission and perinatal outcomes, and factors associated with SARS-CoV-2 status in offspring.
DESIGN: Living systematic review and meta-analysis.
DATA SOURCES: Major databases between 1 December 2019 and 3 August 2021.
STUDY SELECTION: Cohort studies of pregnant and recently pregnant women (including after abortion or miscarriage) who sought hospital care for any reason and had a diagnosis of SARS-CoV-2 infection, and also provided data on offspring SARS-CoV-2 status and risk factors for positivity. Case series and case reports were also included to assess the timing and likelihood of mother-to-child transmission in SARS-CoV-2 positive babies.
DATA EXTRACTION: Two reviewers independently extracted data and assessed study quality. A random effects model was used to synthesise data for rates, with associations reported using odds ratios and 95% confidence intervals. Narrative syntheses were performed when meta-analysis was inappropriate. The World Health Organization classification was used to categorise the timing of mother-to-child transmission (in utero, intrapartum, early postnatal).
RESULTS: 472 studies (206 cohort studies, 266 case series and case reports; 28 952 mothers, 18 237 babies) were included. Overall, 1.8% (95% confidence interval 1.2% to 2.5%; 140 studies) of the 14 271 babies born to mothers with SARS-CoV-2 infection tested positive for the virus with reverse transcriptase polymerase chain reaction (RT-PCR). Of the 592 SARS-CoV-2 positive babies with data on the timing of exposure and type and timing of tests, 14 had confirmed mother-to-child transmission: seven in utero (448 assessed), two intrapartum (18 assessed), and five during the early postnatal period (70 assessed). Of the 800 SARS-CoV-2 positive babies with outcome data, 20 were stillbirths, 23 were neonatal deaths, and eight were early pregnancy losses; 749 babies were alive at the end of follow-up. Severe maternal covid-19 (odds ratio 2.4, 95% confidence interval 1.3 to 4.4), maternal death (14.1, 4.1 to 48.0), maternal admission to an intensive care unit (3.5, 1.7 to 6.9), and maternal postnatal infection (5.0, 1.2 to 20.1) were associated with SARS-CoV-2 positivity in offspring. Positivity rates using RT-PCR varied between regions, ranging from 0.1% (95% confidence interval 0.0% to 0.3%) in studies from North America to 5.7% (3.2% to 8.7%) in studies from Latin America and the Caribbean.
CONCLUSION: SARS-CoV-2 positivity rates were found to be low in babies born to mothers with SARS-CoV-2 infection. Evidence suggests confirmed vertical transmission of SARS-CoV-2, although this is likely to be rare. Severity of maternal covid-19 appears to be associated with SARS-CoV-2 positivity in offspring.
SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42020178076.
READERS' NOTE: This article is a living systematic review that will be updated to reflect emerging evidence. Updates may occur for up to two years from the date of original publication.
参考来源
- Allotey J, Chatterjee S, Kew T, et al. SARS-CoV-2 positivity in offspring and timing of mother-to-child transmission: living systematic review and meta-analysis. BMJ. 2022. PMID: 35296519. doi:10.1136/bmj-2021-067696
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。